BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tolebrutinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tolebrutinib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06372145-7074@assetmemo.bio
DTSTAMP:20261121T010122Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Tolebrutinib: Phase 3 readout est. (NCT06372145)
DESCRIPTION:Tolebrutinib\, phase 3\, Multiple Sclerosis.\nStudy: A Study to
  Investigate Long-term Safety and Tolerability of Tolebrutinib in Particip
 ants With Multiple Sclerosis.\nEstimated primary completion: 30 April 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tolebrutinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06372145
URL:https://assetmemo.bio/drug/tolebrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
